

Filed Pursuant to Rule 433
Registration No. 333-208157
December 7, 2015

RennovaHealth

Solutions Driven By Innovation

Nasdaq: RNVA

Diagnostics and supportive software
solutions to healthcare providers.



Free Writing Prospectus Statement

This presentation highlights basic information about us and the proposed public offering. Because this presentation is a summary, it does not contain all of the information you should consider before investing in our common stock.

We have filed a registration statement (including a preliminary prospectus) with the SEC for the offering. The registration statement has not yet become effective. Before you invest, you should carefully read the preliminary prospectus, the registration statement and any other documents incorporated by reference therein for more complete information about us and this proposed public offering before investing in our common stock.

You may obtain these documents free of charge by searching the SEC online database (EDGAR) on the SEC web site at <http://www.sec.gov>. Alternatively, a copy of the preliminary prospectus relating to the offering may be obtained, when available, by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Ave, 18th floor, New York, NY 10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com.

Forward looking Statements and Non-GAAP Information

This presentation includes forward-looking statements about Rennova Health's anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, objectives, expectations and strategy for the combined businesses, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Rennova Health with the Securities and Exchange Commission. Rennova Health undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances, except to the extent required by applicable law or regulation.

Note: This presentation includes certain "Non-GAAP" financial measures as defined by SEC rules. As required by the SEC, we have provided a reconciliation of those measures to the most directly comparable GAAP measures on the Regulation G slide included as slide 12 of this presentation. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, reported GAAP results.

Offering Summary

Issuer:	Rennova Health, Inc.
Exchange & Ticker:	NASDAQ: RNVA
Expected Offering Size	Approx. \$15,000,000 (Common Stock and Warrants)
Over-Allotment	15% (100% Primary)
Use of Proceeds	Working Capital; General Corporate Purposes; Continued development of new diagnostics processes and methodologies; Possible Acquisitions or Expansions
Sole Book-Runner	Aegis Capital Corp.

RenovaHealth

Solutions Driven By Innovation

NASDAQ: RNVA

Listed on Nasdaq on November 3rd 2015
after completion of a merger between
Medytox Solutions, Inc. and CollabRx, Inc.

Medytox

Solutions & Services For Medical Providers

OTCBB since 2011 (MMMS)


 **CollabRx**
Expert Systems for Precision Medicine

Nasdaq listed since 1995
CollabRx since 2012 (CLRXX)

- We are four years into our business plan with a number of significant milestones already achieved
- We have revenue – Medytox had \$57.9 million of sales in 2014
- Our operations are profitable, with Medytox having positive adjusted EBITDA of \$18.1 million in 2014
- We operate in a sizable and established market place
- We have a capable management team
- We have a solid foundation from which we can grow
 - >95% of current revenues derived from diagnostics
 - Value added products now developed and launched (2015)


Rennova Health, Inc. is a vertically integrated company that provides industry leading Diagnostics and supportive software solutions to healthcare providers.

Rennova Health owns and operates five high-complexity CLIA and CAP certified laboratories strategically located across the U.S



History

Pre-merger numbers from Medytox



Rennova Health, Inc. offers a single source solution for Medical Providers

Our core business is diagnostics: >95% of our revenue currently comes from diagnostics

The diagnostics sector has changed dramatically in the last few years

Medical providers need more than just diagnostics

They need:


- Efficient and easy ordering and reporting
- Electronic health records
- Seamless integration
- Revenue Cycle Management
- Funding and financial solutions
- Interpretation of diagnostics

Rennova products:

- Advantage
- Medical Mime
- Clinlab
- Medical Billing Services
- Platinum Financial Solutions
- CollabRx

Medical providers need an increasing number of integrated and interoperable solutions to enable their business to function

Our solutions can be stand alone or integrated



Drug and Alcohol Rehabilitation

- Total Market Size – estimated at \$35 Billion*
- Large and growing number of facilities in a fragmented market
- Between 14,500 to 16,700 outpatient clinics*
- Market growth from high demand:
- Over 23 million Americans are addicted to alcohol and other drugs**
- The number of Americans in addiction treatment ranges from 2.5 million to 4.1 million***
- 3 to 5 million people who have a diagnostic addiction disorder warranting treatment will gain coverage through healthcare reform****

Pain Management Sector

- Total Market Size – estimated at \$2-\$4 billion*****
- Large and growing number of clinics in a fragmented market
- Private clinics in the U.S. estimated between 1,500 to 2,500
- More than 6,800 doctors specialize in pain management and more than 600,000 doctors are licensed to prescribe pain medication
- Market growth from high demand:
- Chronic pain affects an estimated 100 million Americans, or one-third of the U.S. population*****
Approximately 25 million people experience moderate to severe chronic pain with significant pain-related activity limitations and diminished quality of life*****
- Between 5 to 8 million people use opioids for long-term pain management
- In 2012, U.S. providers wrote 259 million prescriptions for opioid painkillers*****

Market Drivers

Lab Services Drivers

- Secular growth
- Compliance

Value-added services

- Efficiency
- Cost
- Revenue cycle management

Sources:

*IBIS World.

**The National Council on Alcoholism and Drug Dependency.

***SAMHSA.

****National Association of Alcoholism and Drug Abuse Counselors

*****The U.S. Addiction Rehab Market, Bharat

Publication.

*****NIH.

*****CDC and Pain Physician Publication.

2015 Revenue 9 months: \$42.2M

(Pre-Merger numbers from Medytex)


Diagnostics represents >95% of our revenue

Transition year

- Investment in Labs
- Investment in software
- Merger costs
- Billing Company restructure
- Toxicology sector
 - Additional scrutiny by payers and slower payments caused by many Labs who had adopted fraudulent practices

Overhead, merger and investment costs will outweigh profit from operations for 2015

Jan-Sept 2015



Reconciliation of GAAP to Adjusted Measures - Medytox Solutions, Inc. Pre Merger

<i>(in thousands)</i>	2011	2012	2013	2014	Jan-Sep 2015
Net Revenue	\$ 3,993	\$ 21,076	\$ 41,889	\$ 57,928	\$ 28,921
Write-off of receivables aged greater than one year	-	-	-	-	13,298
Adjusted Revenue	\$ 3,993	\$ 21,076	\$ 41,889	\$ 57,928	\$ 42,219
Net Income	\$ 587	\$ 2,747	\$ 7,820	\$ 8,260	\$ (4,499)
Provision for Income Taxes	(172)	481	5,569	7,561	(2,580)
Interest Expense	175	654	475	514	1,595
Depreciation and Amortization	18	66	408	1,500	1,979
EBITDA	608	3,948	14,272	17,835	(3,505)
Write-off of receivables aged greater than one year	-	-	-	-	13,298
Stock Compensation Expense	13	235	63	342	3,380
Merger, Acquisition and Integration Costs	-	-	-	-	925
Adjusted EBITDA	\$ 621	\$ 4,183	\$ 14,335	\$ 18,177	\$ 14,098

Balance Sheet Highlights – September 30, 2015 (pro forma)

Cash	\$	6.7
Accounts Receivable, Net	\$	22.7
Fixed Assets	\$	7.8
Total Assets	\$	48.0
Accounts Payable and Accrued Expenses	\$	7.9
Debt	\$	8.1
Capital Leases	\$	4.0
Total Liabilities	\$	24.6
Working Capital	\$	11.6

Capitalization Table – November 30, 2015

<i>(in millions, except per share amounts)</i>	<u>Weighted Average Price</u>	<u>Shares</u>
Common Stock Issued and Outstanding		13.8
Convertible Preferred Stock		5.7
Convertible Debt		2.0
Warrants	\$ 9.40	0.4
Stock Options	\$ 6.74	1.8
Fully Diluted Shares Outstanding		23.8
<i>Stock Options Anticipated</i>	\$ 7.36	14.8

Management:

- **Seamus Lagan** **CEO**
20 years experience in the restructuring, development and management of startup and small companies
- **Jason Adams** **CFO**
CFO in behavioral health sector and Senior Financial Management of public companies
- **Sebastien Sainsbury** **Investor Relations**
Banking and wealth management and 10 years on the Board of AIG International
- **Steven Burdelski** **Chief Compliance Officer**
25 years with the FBI with responsibility for corporate and legal compliance to improve performance
- **Frank Dias** **Business Development and Sales**
Entrepreneur with 25 years experience in sales and logistics
- **Tiffany Vandemark** **Marketing Director**
15 years in marketing. Oversaw the launch and first four years of Chobani (Greek yogurt)
- **Dr. William DePond** **COO of Lab Operations and CEO of each Lab**
Board certified in Anatomic and Clinical Pathology with 2 years in management at Quest Diagnostics
- **Dean Viskovich** **In-House counsel**
25 years experience as a trial and defense attorney in the healthcare sector
- **Charles Darcy** **Compliance Officer**
COO in hospitals with Bachelors degree in Laboratory Science and Masters degree in Health Administration

Board:

- **Thomas Mika** **Chairman of Rennova, CEO of CollabRx (subsidiary)**
10 years as Chairman and CEO of a Nasdaq listed Company. Oversaw a number of public offerings. Holds a Bachelor of Science degree in Microbiology, MBA Harvard
- **Seamus Lagan** **CEO**
20 years experience in the restructuring, development and management of startup and small companies
Founder, investor and shareholder
- **Christopher Diamantis** **Director**
Chairman and CEO of Integrated Financial Settlements, Inc., a structured settlement consulting firm. Acts as Chairman and a director of a number of Banks
- **Michael Goldberg** **Director**
16 years as CEO of an AMEX-listed healthcare company that acquired 23 labs and 2 hospitals under his tenure
- **Dr. Paul Billings** **Director**
A nationally recognized expert on genomic and precision medicine. Has served as Chief Medical Officer or Director of some of the nation's largest health care companies
- **Benjamin Frank** **Director**
Retired lawyer and businessman who served as Chairman of the Board of the Healthcare District of Palm Beach County
- **Robert Lee** **Director**
16 years as a Managing Director of Morgan Stanley Dean Witter and Managing Director of the M&A group at Morgan Stanley, where he worked closely with financial sponsors. Chairman of numerous audit committees

Current and Future Products Dashboard

	Existing	2015	2016	2017	Future
Point of care test for Diabetes Test that will move from Lab to Doctors office (Epinex)				Launch	
Cancer diagnostics (DNA Sequencing)		In planning		Launch	
Self Directed Consumer Testing Two hurdles - Collection and Interpretation			Launch		
Roll out Financial Solution		In planning	Launch		
Roll out Medical Billing Solution		In planning	Launch		
Roll out EHR Product		Launch			
Development of additional diagnostics that we have current capability to deliver			Launch		
Capitalize on current disruption in Toxicology sector		In planning			
Expand our current diagnostics business and related sales efforts across the nation		Launch			

In planning
 Development
 Launch
 Operational

Key Highlights

- We are four years into our business plan with a number of significant milestones already achieved
- We have revenue – Medytox had \$57.9 million of sales in 2014
- Our operations are profitable, with Medytox having positive adjusted EBITDA of \$18.1 million in 2014
- We operate in a sizable and established market place
- We have a capable management team
- We have a solid foundation from which we can grow
 - >95% of current revenues derived from diagnostics
 - Value added products now developed and launched (2015)